By admin on September 2, 2014 -
August 29, 2014 – A federal judge rejected a bid by top Japanese drugmaker Takeda Pharmaceutical and Eli Lilly & Co. on August 28 to throw out a $9 billion punitive damage award for hiding the cancer risks of their diabetes drug, Actos®.
The combined $9 billion award stems from a March 8 ruling when jurors found that Takeda and Lilly acted with “wanton and reckless disregard” in their promotion and marketing of Actos. The Court ordered Takeda to pay $6 billion of the award, and Lilly to pay $3 billion. Read the rest »
By admin on September 26, 2013 -
A Maryland jury found that Takeda Pharmaceutical Co. did not properly warn Diep An, an ex-U.S. Army translator, and his doctor about the risks of its Actos® diabetes drug and ordered the company to pay more than $1.7 million in damages. The judge immediately threw out the Plaintiff’s verdict on a technicality based on Maryland law.
This is the second time a U.S. jury has found Takeda failed to adequately warn of the bladder cancer risks of Actos to its users. This is also the second time a judge has overturned a Plaintiff’s verdict against Takeda. Under Maryland law, if a Plaintiff is even one percent at fault, the Plaintiff cannot recover. An was a thirty year smoker – a factor that the jury found had some tendancy to contribute to his injuries. Takeda is currently facing more than 3,000 suits regarding its link to an increased risk of developing bladder cancer.
Read the rest »
By admin on May 1, 2013 -
On Friday, April 26, 2013, a Los Angeles jury awarded $6.5 million to the plaintiff, finalizing the suit filed against Japanese pharmaceutical company, Takeda Pharmaceuticals, for hiding the link between Actos® and the high risk of bladder cancer. The action was brought by 79-year-old Jack Cooper, who was diagnosed with bladder cancer after taking Actos for five years.
This verdict is a strong first step in the pursuit of justice for the many Actos users who have been harmed by the drug. Our attorneys at Robinson Calcagnie Robinson Shapiro Davis, Inc. have represented many clients in pharmaceutical litigation and hope that the lawsuits that follow this verdict in the ongoing Actos matter are equally successful.
Read the rest »